Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

2.1K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
2.1K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

2.1K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
2.1K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

1.2K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.2K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

692
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
692
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

953
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
953
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Desmoglein-2 dysregulation impairs epithelial barrier integrity in eosinophilic asthma.

Respiratory research·2026
Same author

MiR-146a-armed exosomes reverse immunosuppressive networks in NSCLC by dual-targeting of MYD88/STAT3 and PD-L1 axes.

International immunopharmacology·2026
Same author

CD207-Positive Dendritic Cells Promote Emphysema Through CD8<sup>+</sup> T Cell Pathway in Chronic Obstructive Pulmonary Disease.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Nasal gene expression shows a distinct signature in type 2-high asthma but not in type 2-low disease.

The Journal of allergy and clinical immunology·2026
Same author

Type 2 Biomarkers as Mediators of Clinical Remission With Biologics in Severe Asthma.

Allergy·2025
Same author

Proteomic and Transcriptomic Signatures of Poor Asthma Symptom Control in the U-BIOPRED Cohort.

Allergy·2025

Related Experiment Video

Updated: May 4, 2026

Biochemical Reconstitution of Steroid Receptor&#x2022;Hsp90 Protein Complexes and Reactivation of Ligand Binding
11:07

Biochemical Reconstitution of Steroid Receptor•Hsp90 Protein Complexes and Reactivation of Ligand Binding

Published on: September 21, 2011

14.4K

Molecular interactions between glucocorticoids and long-acting beta2-agonists.

Ian M Adcock1, Kittipong Maneechotesuwan, Omar Usmani

  • 1Department of Thoracic Medicine, National Heart and Lung Institute, Imperial College of Science, Technology and Medicine, London, UK.

The Journal of Allergy and Clinical Immunology
|December 5, 2002
PubMed
Summary

Beta(2)-adrenergic agonists and glucocorticoids are effective asthma treatments. They enhance each other

More Related Videos

A Chemical Screening Procedure for Glucocorticoid Signaling with a Zebrafish Larva Luciferase Reporter System
13:22

A Chemical Screening Procedure for Glucocorticoid Signaling with a Zebrafish Larva Luciferase Reporter System

Published on: September 10, 2013

13.3K
Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids
08:02

Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids

Published on: April 25, 2016

9.1K

Related Experiment Videos

Last Updated: May 4, 2026

Biochemical Reconstitution of Steroid Receptor&#x2022;Hsp90 Protein Complexes and Reactivation of Ligand Binding
11:07

Biochemical Reconstitution of Steroid Receptor•Hsp90 Protein Complexes and Reactivation of Ligand Binding

Published on: September 21, 2011

14.4K
A Chemical Screening Procedure for Glucocorticoid Signaling with a Zebrafish Larva Luciferase Reporter System
13:22

A Chemical Screening Procedure for Glucocorticoid Signaling with a Zebrafish Larva Luciferase Reporter System

Published on: September 10, 2013

13.3K
Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids
08:02

Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids

Published on: April 25, 2016

9.1K

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Immunology

Background:

  • Asthma treatment relies on beta(2)-adrenergic agonists and glucocorticoids, which are more effective in combination.
  • Glucocorticoids exert anti-inflammatory effects via activated glucocorticoid receptors (GRs), influencing gene synthesis through DNA binding regions.
  • GRs down-regulate inflammatory mediators by repressing transcription factors like activator protein-1 and nuclear factor kappaB.

Purpose of the Study:

  • To investigate the molecular mechanisms underlying the synergistic effects of beta(2)-adrenergic agonists and glucocorticoids in asthma treatment.
  • To explore how these treatments modulate glucocorticoid receptor (GR) and beta(2)-adrenergic receptor (BAR) function and interaction.

Main Methods:

  • Analysis of gene expression and protein phosphorylation in human lung cells.
  • Investigation of GR nuclear localization and transcriptional activity.
  • Assessment of BAR function, including G-protein coupling and receptor downregulation.

Main Results:

  • Long-acting beta(2)-agonists may influence GR nuclear localization and function through phosphorylation.
  • Glucocorticoids can enhance beta(2)-adrenergic receptor expression and function, restoring G-protein coupling and preventing desensitization.
  • Combined treatment demonstrates a synergistic effect, likely due to reciprocal modulation of GR and BAR pathways.

Conclusions:

  • The combination of beta(2)-adrenergic agonists and glucocorticoids offers enhanced therapeutic benefits in asthma.
  • Reciprocal regulation between GR and BAR signaling pathways contributes to their synergistic effects.
  • Targeting these interactions may lead to improved asthma management strategies.